Literature DB >> 78901

Specificity of the blastogenic response of human mononuclear cells to herpesvirus antigens.

J A Zaia, P L Leary, M J Levin.   

Abstract

Peripheral blood mononuclear (PBM) cells from donors with a history of prior infection with herpes simplex virus, varicella-zoster virus, and/or cytomegalovirus were cultured for 2 to 8 days with glycine-extracted antigens prepared from these viruses and from infectious bovine rhinotracheitis virus. The proliferative response of PBM cells from all donors was specific during the first 6 days in culture. During this period the cellular immune responses of the seronegative donors were clearly different from those of the seropositive donors. The responses of PBM cells in culture with any of the human herpesvirus antigens studied was not influenced by prior infection of the donor with one or more other human herpesviruses. In contrast, although no donors had antibody to infectious bovine rhinotracheitis virus, the PBM cells from some of them had a proliferative response to this bovine herpesvirus, which increased with time. This nonspecific response appears to be a host-associated function which may be related to recognition of a common herpesvirus antigen.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 78901      PMCID: PMC421907          DOI: 10.1128/iai.20.3.646-651.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  SEROLOGICAL COMPARISON OF THE HERPES VIRUSES.

Authors:  G PLUMMER
Journal:  Br J Exp Pathol       Date:  1964-04

2.  POSSIBLE ANTIGENIC RELATIONSHIP BETWEEN VARICELLA ZOSTER VIRUS AND HERPES SIMPLEX VIRUS.

Authors:  J G KAPSENBERG
Journal:  Arch Gesamte Virusforsch       Date:  1964-09-09

3.  Herpes simplex virus microneutralization: a simplification of the test.

Authors:  H Stalder; M N Oxman; K L Herrmann
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

4.  Cellular immune responses to Herpes simplex virus type 1 in recurrent herpes labialis: in vitro blastogenesis and cytotoxicity to infected cell line.

Authors:  R W Steele; M M Vincent; S A Hensen; D A Fuccillo; I A Chapa; L Canales
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

5.  Stimulation of human lymphocytes by Herpes simplex virus antigens.

Authors:  S E Starr; S A Karatela; S L Shore; A Duffey; A J Nahmias
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

6.  Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells.

Authors:  J A Zaia; M N Oxman
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

7.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

8.  Blastogenic response of human lymphocytes to human cytomegalovirus.

Authors:  J L Waner; J E Budnick
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

9.  The demonstration of cell-associated immunity to viruses. In vitro lymphocyte responsiveness to Varicella-zoster antigen.

Authors:  J C Ruckdeschel; M R Mardiney
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

View more
  26 in total

1.  Specificity of skin test with varicella-zoster virus antigen in varicella-zoster and herpes simplex virus infections.

Authors:  K Baba; K Shiraki; T Kanesaki; K Yamanishi; P L Ogra; H Yabuuchi; M Takahashi
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

2.  Processing and presentation of cell-associated varicella-zoster virus antigens by human monocytes.

Authors:  O Pontesilli; P Carotenuto; M J Levin; D Suez; A R Hayward
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

3.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

4.  Proliferative and interferon responses by peripheral blood mononuclear cells after bone marrow transplantation in humans.

Authors:  M J Levin; R Parkman; M N Oxman; J M Rappeport; M Simpson; P L Leary
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

5.  Cloned bovine cytolytic T cells recognize bovine herpes virus-1 in a genetically restricted, antigen-specific manner.

Authors:  G A Splitter; L Eskra; A F Abruzzini
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

6.  Enumeration of viral antigen-reactive helper T lymphocytes in human peripheral blood by limiting dilution for analysis of viral antigen-reactive T-cell pools in virus-seropositive and virus-seronegative individuals.

Authors:  K A Clouse; P W Adams; C G Orosz
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

7.  Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs.

Authors:  A R Hayward; R Burger; R Scheper; A M Arvin
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Correlation of herpes simplex virus antibody titers and specific lymphocyte stimulation in adult blood donors.

Authors:  H Moser; F Behrens; R Ziegelmaier; J Hilfenhaus; R Mauler
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

9.  Lymphocyte blastogenesis and interferon production in adult human leukocyte cultures stimulated with cytomegalovirus antigens.

Authors:  S E Starr; B Dalton; T Garrabrant; K Paucker; S A Plotkin
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

10.  Inhibition of herpes simplex virus type 1 replication in fibroblast cultures by human blood mononuclear cells.

Authors:  P J Leibson; M Hunter-Laszlo; A R Hayward
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.